Astellas – Japanese Innovations for Patient Health
Astellas
Astellas Pharma Inc. is a Japanese pharmaceutical company formed on 1 April 2005 through the merger of Yamanouchi Pharmaceutical (founded in 1923) and Fujisawa Pharmaceutical (founded in 1894). It is headquartered in Tokyo, and its shares trade on the Tokyo Stock Exchange as part of the Nikkei 225 index.
Astellas focuses on oncology, urology, transplantation, ophthalmology and women's health. Its well-known medicines include Vesicare (solifenacin) for overactive bladder, Padcev (enfortumab vedotin) for bladder cancer, Xospata (gilteritinib) for acute myeloid leukaemia and Veozah (fezolinetant) for menopausal hot flushes. Astellas acquired OSI Pharmaceuticals in 2010 and Iveric Bio, a developer of retinal disease treatments, in 2023.
In transplantation the company is known for tacrolimus, discovered at Fujisawa in 1984. Its tacrolimus products, Prograf and the once-daily prolonged-release Advagraf, are used to prevent organ rejection after transplantation.
Enzalutamide (Xtandi) for prostate cancer was created by Medivation and brought to market in partnership with Astellas; the FDA approved it in 2012. Astellas now co-markets Xtandi with Pfizer, which acquired Medivation in 2016.
Unifarm carries Astellas medicines: Advagraf (tacrolimus) and Xtandi (enzalutamide).